Cargando…
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments
PURPOSE OF REVIEW: The chimeric antigen receptor (CAR) T-cell therapy is currently changing the landscape of hematologic malignancies with multiple FDA-approved cell therapy products in the USA. The current administration process of the CAR T-cell therapy is complicated, labor-intensive, and expensi...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179081/ https://www.ncbi.nlm.nih.gov/pubmed/34089485 http://dx.doi.org/10.1007/s11899-021-00635-3 |